Variants in tamoxifen metabolizing genes: A case-control study of contralateral breast cancer risk in the WECARE study

International Journal of Molecular Epidemiology and Genetics

Volumn 4, Issue 1, 2013, Pages 35-48

  Brooks, Jennifer D ^a   Teraoka, Sharon N ^b   Malone, Kathleen E ^c   Haile, Robert W ^d   Bernstein, Leslie ^e   Lynch, Charles F ^f   Mellemkjær, Lene ^g   Duggan, David J ^h   Reiner, Anne S ^a   Concannon, Patrick ^b   Schiermeyer, Katherine ⁱ   Lewinger, Juan Pablo ^j   Bernstein, Jonine L ^a   Figueiredo, Jane C ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^h Translational Genomic Research Institute   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

Contralateral breast cancer; Single nucleotide polymorphisms; Tamoxifen

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CONTRALATERAL BREAST CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84875388654     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE and Daling JR. Population-Based Study of Tamoxifen Therapy and Subsequent Ovarian, Endometrial, and Breast Cancers. J Natl Cancer Inst 1995; 87: 1359-1364.
3. Gajalakshmi CK, Shanta V and Hakama M. Risk factors for contralateral breast cancer in Chennai (Madras), India. Int J Epidemiol 1998; 27: 743-750.
4. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen Therapy for Primary Breast Cancer and Risk of Contralateral Breast Cancer. J Natl Cancer Inst 2001; 93: 1008-1013.
5. Bertelsen L, Bernstein L, Olsen JH, Mellemkjær L, Haile RW, Lynch CF, Malone KE, Anton- Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD Jr, Shore RE; The Women's Environment C, Radiation Epidemiology Study Collaborative Group and Bernstein JL. Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 2008; 100: 32-40.
6. Brauch H, Mürdter TE, Eichelbaum M and Schwab M. Pharmacogenomics of Tamoxifen Therapy. Clin Chem 2009; 55: 1770-1782.
7. Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters. Drug Metab Pharmacokinet 2012; 27: 122-31.
8. Cronin-Fenton DP and Lash TL. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 2011; 4: 363-377.
9. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF and Ambrosone CB. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91: 249-258.
10. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M and Brauch H. Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes. J Clin Oncol 2007; 25: 5187-5193.
11. Goetz M, Knox S, Suman V, Rae J, Safgren S, Ames M, Visscher D, Reynolds C, Couch F, Lingle W, Weinshilboum R, Fritcher E, Nibbe A, Desta Z, Nguyen A, Flockhart D, Perez E and Ingle J. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113-121.
12. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ and Ro J. Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast Cancer. J Clin Oncol 2007; 25: 3837-3845.
13. Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U and Decensi AU. Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial. J Clin Oncol 2006; 24: 3708-3709.
14. Stingl JC,Parmar S,Huber-Wechselberger A,Kainz A,Renner W,Seeringer A,Brockmöller J,Langsenlehner U,Krippl P and Haschke-Becher E. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin 2010; 26: 2535-2542.
15. Bijl M, van Schaik R, Lammers L, Hofman A, Vulto A, van Gelder T, Stricker B and Visser L. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009; 118: 125-130.
16. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B and Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9: R7.
17. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L and Hamilton-Dutoit S. CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark. J Natl Cancer Inst 2011; 103: 489-500.
18. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J and Dowsett M. CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. J Natl Cancer Inst 2012; 104: 452-460.
19. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM and Viale G. CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst 2012; 104: 441-451.
20. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A and Cuzick J. Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. J Clin Oncol 2010 Jul 20; 28: 3411-5.
21. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA and Ingle JN. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes. J Clin Oncol 2005; 23: 9312-9318.
22. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF and Ambrosone CB. Association Between Sulfotransferase 1A1 Genotype and Survival of Breast Cancer Patients Receiving Tamoxifen Therapy. J Natl Cancer Inst 2002; 94: 1635-1640.
23. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE and Wingren S. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7: R284-R290.
24. Grabinski JL, Smith LS, Chisholm GB, Drengler R, Rodriguez GI, Lang AS, Kalter SP, Garner AM, Fichtel LM, Hollsten J, Pollock BH and Kuhn JG. Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Res Treat 2006; 95: 13-16.
25. Singh MS, Francis PA and Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2011; 20: 111-118.
26. Pharoah PDP, Abraham J and Caldas C. Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. J Natl Cancer Inst 2012; 104: 1263-1264.
27. Stanton V. Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst 2012; 104: 1265-1266.
28. Nakamura Y, Ratain MJ, Cox NJ, Mcleod HL, Kroetz DL and Flockhart DA. Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst 2012; 104: 1264.
29. Bernstein J, Langholz B, Haile R, Bernstein L, Thomas D, Stovall M, Malone K, Lynch C, Olsen J, Anton-Culver H, Shore R, Boice J, Berkowitz G, Gatti R, Teitelbaum S, Smith S, Rosenstein B, Borresen-Dale AL, Concannon P and Thompson WD. Study design: Evaluating gene-environment interactions in the etiology of breast cancer-the WECARE study. Breast Cancer Res 2004; 6: R199-R214.
30. Brooks J, John E, Mellemkjær L, Reiner A, Malone K, Lynch C, Figueiredo J, Haile R, Shore R, Group TWSC, Bernstein J, Bernstein L. Body mass index and risk of second primary breast cancer: The WECARE Study. Breast Cancer Res Treat 2012 Jan; 131: 571-80.
31. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA and Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
32. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ and Sham PC. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am J Hum Genet 2007; 81: 559-575.
33. Brooks JD, Teraoka SN, Reiner AS, Satagopan JM, Bernstein L, Thomas DC, Capanu M, Stovall M, Smith SA, Wei S, Shore RE, Boice JD, Lynch CF, Mellemkjær L, Malone KE, Liang X, the WSCG, Haile RW, Concannon P and Bernstein JL. Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. Hum Mutat 2012; 33: 158-164.
34. Lee CR, Goldstein JA,Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-263.
35. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. Clin Pharmacokinet 2002; 41: 913-58.
36. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS and Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
37. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T and Wilking N. Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies. J Natl Cancer Inst 1995; 87: 645-651.
38. Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.
39. Jordan VC. The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice. Clin Cancer Res 2006; 12: 5010-5013.
40. Jordan V. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 2007; 72: 829-842.
41. Furr BJA and Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205.
42. Lim YC, Desta Z, Flockhart DA., Skaar TC. Endoxifen(4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005; 55: 471-478.
43. Novielli A, Bhargava P, Hayes DF, Desta Z and Flockhart DA. Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine. J Natl Cancer Inst 2003; 95: 1758-1764.
44. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM and Lien EA. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008 Jan; 19: 56-61.
45. Thompson A, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray S, Purdie C, Jordan L, Ferraldeschi R, Latif A, Hadfield K, Clarke R, Ashcroft L, Evans D, Howell A, Nikoloff M, Lawrence J and Newman W. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 2011; 125: 279-287.
46. Abraham J, Maranian M, Driver K, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl H, Dunning A, Pharoah P and Caldas C. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010; 12: R64.
47. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M and Brauch H. Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. Clin Pharmacol Ther 2011; 89: 708-717.
48. Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug J, Mellgren G, Steen V and Lien E. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 2010; 10: 313.
49. Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK and Flaws JA. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett 2005; 217: 61-72.
50. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA and Weinshilboum RM. Phenol Sulfotransferase Pharmacogenetics in Humans: Association of CommonSULT1A1Alleles with TS PST Phenotype. Biochem Biophys Res Commun 1997; 239: 298-304.
51. Nowell S, Ambrosone CB, Ozawa S, MacLeod SL, Mrackova G, Williams S, Plaxco J, Kadlubar FF and Lang NP. Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol. Pharmacogenetics 2000; 10: 789-797.
52. Levesque E, Beaulieu M, Green M, Tephly T, Belanger A and Hum D. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7: 317-325.
53. Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Søiland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL and Hamilton-Dutoit S. Functional Polymorphisms in UDP-Glucuronosyl Transferases and Recurrence in Tamoxifen-Treated Breast Cancer Survivors. Cancer Epidemiol Biomarkers Prev 2011; 20: 1937-1943.
54. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle J., Eichelbaum M, Schwab M and Brauch H. Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. JAMA 2009; 302: 1429-1436.
55. Abrams JS. Tamoxifen: Five Versus Ten Years- Is the End in Sight? J Natl Cancer Inst 2001 May 2; 93: 662-4.
56. The Early Breast Cancer Trialists's Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.